The estimated Net Worth of Michael D. Rogers is at least $18.6 Thousand dollars as of 23 March 2015. Michael Rogers owns over 6,372 units of Chimerix Inc stock worth over $18,602 and over the last 11 years Michael sold CMRX stock worth over $0.
Michael has made over 2 trades of the Chimerix Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Michael exercised 6,372 units of CMRX stock worth $48,236 on 23 March 2015.
The largest trade Michael's ever made was exercising 13,000 units of Chimerix Inc stock on 25 April 2014 worth over $98,410. On average, Michael trades about 3,229 units every 55 days since 2014. As of 23 March 2015 Michael still owns at least 21,630 units of Chimerix Inc stock.
You can see the complete history of Michael Rogers stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, STE. 340, DURHAM, NC, 27713.
Over the last 12 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex, and Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Chimerix Inc executives and other stock owners filed with the SEC include: